Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd...
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
About this item
Full title
Author / Creator
Tan, Carlyn Rose , Derkach, Andriy , Nemirovsky, David , Ciardiello, Amanda , Diamond, Benjamin , Hultcrantz, Malin , Hassoun, Hani , Mailankody, Sham , Shah, Urvi , Maclachlan, Kylee , Patel, Dhwani , Lahoud, Oscar B. , Landau, Heather J. , Chung, David J. , Shah, Gunjan L. , Scordo, Michael , Giralt, Sergio A. , Lesokhin, Alexander , Usmani, Saad Z. , Landgren, Ola and Korde, Neha
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed multiple myeloma, 198 received VRd and 191 receive...
Alternative Titles
Full title
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Authors, Artists and Contributors
Author / Creator
Derkach, Andriy
Nemirovsky, David
Ciardiello, Amanda
Diamond, Benjamin
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi
Maclachlan, Kylee
Patel, Dhwani
Lahoud, Oscar B.
Landau, Heather J.
Chung, David J.
Shah, Gunjan L.
Scordo, Michael
Giralt, Sergio A.
Lesokhin, Alexander
Usmani, Saad Z.
Landgren, Ola
Korde, Neha
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_cffbd554fa414cab9e44d309fb48abab
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_cffbd554fa414cab9e44d309fb48abab
Other Identifiers
ISSN
2044-5385
E-ISSN
2044-5385
DOI
10.1038/s41408-023-00882-y
